Table 2.
Univariate and multivariate logistic regression for primary ADT failure
| Univariate | Multivariate | |||
|---|---|---|---|---|
| OR | CI 95% | OR | CI 95% | |
| Age, years | ||||
| <65 | 1.00 | Ref. | – | – |
| 65–74 | 1.28 | 0.65–2.78 | – | – |
| ≥75 | 1.73 | 0.88–3.75 | – | – |
| Initial treatment | ||||
| Polyestradiol phosphate | 1.00 | Ref. | – | – |
| TAB | 1,16 | 0.75–1.78 | – | – |
| Cardiovascular comorbidity | ||||
| None | 1.00 | Ref. | – | – |
| Present | 1,47 | 0.75–2.67 | – | – |
| Cancer‐related pain | ||||
| No pain | 1.00 | Ref. | 1.00 | Ref. |
| Pain | 2.69 | 1.65–4.56 | 0.53 | 0.22–1.27 |
| ECOG Performance status | ||||
| 0 | 1.00 | Ref. | 1.00 | Ref. |
| 1 | 3.99 | 2.28–7.35 | 3.09 | 1.65–6.09 |
| 2–3 | 5.58 | 2.96–10.88 | 3.47 | 1.67–7.44 |
| Analgesic consumption | ||||
| Negligible | 1.00 | Ref. | 1.00 | Ref. |
| ≥1 | 3.58 | 2.20–6.06 | 2.92 | 1.25–7.22 |
| Grade of malignancy | ||||
| WHO 1 | 1.00 | Ref. | – | – |
| WHO 2 | 0.92 | 0.48–1.91 | – | – |
| WHO 3 | 1.54 | 0.81–3.13 | – | – |
| T‐category | ||||
| T0–T2 | 1.00 | Ref. | 1.00 | Ref. |
| T3–T4 | 1.86 | 1.03–3.67 | 1.80 | 0.95–3.73 |
| PSA, μg/L | ||||
| PSA <100 | 1.00 | Ref. | – | – |
| PSA 100–500 | 1.03 | 0.61–1.77 | – | – |
| PSA >500 | 1.20 | 0.69–2.13 | – | – |
| Soloway score | ||||
| 1 | 1.00 | Ref. | 1.00 | Ref. |
| 2–3 | 3.43 | 1.97–6.41 | 2.22 | 1.24–4.25 |
| Hemoglobin, g/L | ||||
| High | 1.00 | Ref. | 1.00 | Ref. |
| Low | 2.11 | 1.35–3.35 | 1.65 | 1.03–2.69 |
| SHBG | ||||
| Low | 1.00 | Ref. | – | – |
| High | 1.43 | 0.50–4.27 | – | – |
| Estradiol | ||||
| Low | 1.00 | Ref. | – | – |
| High | 0.86 | 0.28–2.55 | – | – |
| Testosterone | ||||
| Low | 1.00 | Ref. | – | – |
| High | 0.72 | 0.45–1.13 | – | – |